Sarissa Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Sarissa Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13	Closed	-$564K	–	10
2018 Q2	$564K	Hold	13	–	–	0.11%	9
2018 Q1	$587K	Hold	13	–	–	0.14%	10
2017 Q4	$2.66M	Hold	13	–	–	0.68%	10
2017 Q3	$2.48M	Hold	13	–	–	0.76%	7
2017 Q2	$1.64M	Hold	13	–	–	0.55%	7
2017 Q1	$3.06M	Hold	13	–	–	1.21%	7
2016 Q4	$1.88M	Hold	13	–	–	0.52%	9
2016 Q3	$4.9M	Hold	13	–	–	1.13%	10
2016 Q2	$5.78M	Hold	13	–	–	1.64%	10
2016 Q1	$8.41M	Buy	13 +7	+117%	+$8.6M	1.85%	12
2015 Q4	$6.46M	Hold	6	–	–	1.26%	11
2015 Q3	$9.53M	Hold	6	–	–	2.35%	11
2015 Q2	$11.2M	Hold	6	–	–	2.57%	9
2015 Q1	$12.2M	Buy	6 +5	+500%	+$10.3M	2.57%	9
2014 Q4	$1.03M	Buy	+1	New	+$1.52M	0.36%	14

Other funds holding SEEL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sarissa Capital Management's SEEL Position: Q3 2018 in Review

Sarissa Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2018, closing a stake of 13 shares — an estimated $564K sold.

Sarissa Capital Management first reported a position in SEEL in Q4 2014 and held it in 15 quarters. The position peaked at $12.2M in Q1 2015. 6 funds tracked by Wall St. Rank hold SEEL as of Q3 2018.

Sarissa Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Sarissa Capital Management sold 13 Seelos Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $564K.
Sarissa Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
Sarissa Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $12.2M in Q1 2015.
6 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Sarissa Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.